Open Access

Expression of Bcl-2 and Bad in hippocampus of status epileptic rats and molecular mechanism of intervened recombinant human erythropoietin

  • Authors:
    • Jianghua Yu
    • Zhiqin Shi
    • Xudong Su
    • Yi Zhou
    • Bin Li
    • Shan Wang
    • Lijing Jia
    • Bo Zhao
    • Mengchu Zhu
    • Xiaohong Feng
    • Kuochang Yin
    • Weiping Wang
  • View Affiliations

  • Published online on: June 5, 2018     https://doi.org/10.3892/etm.2018.6250
  • Pages: 847-855
  • Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Injury of hippocampal neurons in status epilepticus (SE) SD rats kindled by pentylenetetrazol (PTZ) were studied, and the changes of apoptosis neurons, protein expression of Bad and Bcl-2 alone and combined application of phosphatidyl inositol 3-kinase (PI3K) inhibitor LY294002 and recombinant human erythropoietin (rHuEpo) were evaluated for the possible mechanisms of rHuEpo. The SE rats kindled by the PTZ were randomly divided into normal control group [normal saline (NS)], model group (PTZ + NS), rHuEpo treated group (PTZ + rHuEpo), LY294002 treated group (PTZ + LY294002 + rHuEpo) and LY294002 control group (rHuEpo + PTZ + DMSO). Apoptosis of hippocampal neurons was detected by TUNEL method; expression of phosphorylation protein kinase B (p-PKB/p-Akt), Bcl-2 and Bad were detected by immunohistochemistry; the expression of Bcl-2 mRNA, Bad mRNA in hippocampal neurons of rats were detected through reverse transcription polymerase chain reaction (RT-PCR); the expression of Akt, p-Akt and Bcl-2, Bad protein in hippocampal neurons of rats were detected by western blotting. The amount of apoptotic neurons was less in the rHuEpo treated group and the LY294002 control group than in the LY294002 treated group (P<0.05). The expression of p-Akt protein and Bcl-2 protein increased while the Bad protein decreased significantly in the rHuEpo treated group and the LY294002 control group compared with the LY294002 treated group (P<0.05). The expression of Bad protein and Bad mRNA in hippocampus increased while the p-Akt, Bcl-2, Bcl-2 mRNA decreased significantly in the LY294002 treated group compared with the rHuEpo treated group (P<0.05). The PI3K/Akt signaling pathway is one of the pathways of rHuEpo neuroprotective effects and was confirmed from both the of positive and negative aspects. rHuEpo regulates the expression of mitochondrial apoptotic pathway related factors Bad and Bcl-2 to inhibit apoptosis and promotes neuronal survival.
View Figures
View References

Related Articles

Journal Cover

August-2018
Volume 16 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yu J, Shi Z, Su X, Zhou Y, Li B, Wang S, Jia L, Zhao B, Zhu M, Feng X, Feng X, et al: Expression of Bcl-2 and Bad in hippocampus of status epileptic rats and molecular mechanism of intervened recombinant human erythropoietin. Exp Ther Med 16: 847-855, 2018
APA
Yu, J., Shi, Z., Su, X., Zhou, Y., Li, B., Wang, S. ... Wang, W. (2018). Expression of Bcl-2 and Bad in hippocampus of status epileptic rats and molecular mechanism of intervened recombinant human erythropoietin. Experimental and Therapeutic Medicine, 16, 847-855. https://doi.org/10.3892/etm.2018.6250
MLA
Yu, J., Shi, Z., Su, X., Zhou, Y., Li, B., Wang, S., Jia, L., Zhao, B., Zhu, M., Feng, X., Yin, K., Wang, W."Expression of Bcl-2 and Bad in hippocampus of status epileptic rats and molecular mechanism of intervened recombinant human erythropoietin". Experimental and Therapeutic Medicine 16.2 (2018): 847-855.
Chicago
Yu, J., Shi, Z., Su, X., Zhou, Y., Li, B., Wang, S., Jia, L., Zhao, B., Zhu, M., Feng, X., Yin, K., Wang, W."Expression of Bcl-2 and Bad in hippocampus of status epileptic rats and molecular mechanism of intervened recombinant human erythropoietin". Experimental and Therapeutic Medicine 16, no. 2 (2018): 847-855. https://doi.org/10.3892/etm.2018.6250